phd hematology

Study at Cambridge

About the university, research at cambridge.

• Undergraduate courses
• Events and open days
• Fees and finance
• Postgraduate courses
• How to apply
• Postgraduate events
• Fees and funding
• International students
• Continuing education
• Executive and professional education
• Courses in education
• How the University and Colleges work
• Term dates and calendars
• Visiting the University
• Annual reports
• Equality and diversity
• A global university
• Public engagement
• Give to Cambridge
• For Cambridge students
• For our researchers
• Business and enterprise
• Colleges & departments
• Email & phone search
• Museums & collections
• Course Directory

PhD in Haematology

Postgraduate Study

• Why Cambridge overview
• Chat with our students
• Cambridge explained overview
• The supervision system
• Student life overview
• In and around Cambridge
• Leisure activities
• Student unions
• Music awards
• Student support overview
• Mental health and wellbeing
• Disabled students
• Accommodation
• Language tuition
• Skills training
• Support for refugees
• Courses overview
• Department directory
• Qualification types
• Funded studentships
• Part-time study
• Research degrees
• Visiting students
• Finance overview
• Fees overview
• What is my fee status?
• Part-time fees
• Application fee
• Living costs
• Funding overview
• Funding search
• How to apply for funding
• University funding overview
• Research Councils (UKRI)
• External funding and loans overview
• Funding searches
• External scholarships
• Charities and the voluntary sector
• Funding for disabled students
• Widening participation in funding
• Colleges overview
• What is a College?
• Choosing a College
• Applying overview
• Before you apply
• Entry requirements
• Application deadlines
• How do I apply? overview
• Application fee overview
• Application fee waiver
• Life Science courses
• Terms and conditions
• Continuing students
• Disabled applicants
• Supporting documents overview
• Academic documents
• Finance documents
• Evidence of competence in English
• AI and postgraduate applications
• Terms and Conditions
• Applicant portal and self-service
• After you apply overview
• Confirmation of admission
• Student registry
• Previous criminal convictions
• Deferring an application
• Updating your personal details
• Appeals and Complaints
• Widening participation
• Postgraduate admissions fraud
• International overview
• Immigration overview
• ATAS overview
• Applying for an ATAS certificate
• Current Cambridge students
• International qualifications
• Competence in English overview
• What tests are accepted?
• International events
• International student views overview
• Akhila’s story
• Alex’s story
• Huijie’s story
• Kelsey’s story
• Nilesh’s story
• Get in touch!
• Events overview
• Upcoming events
• Postgraduate Open Days overview
• Discover Cambridge: Master’s and PhD Study webinars
• Virtual tour
• Research Internships
• How we use participant data
• Postgraduate Newsletter

Primary tabs

• Overview (active tab)
• Requirements
• How To Apply

The Department of Haematology is located on the Cambridge Biomedical Campus. Research in the department falls into three main areas with major relevance for human disease: The Haematopoiesis and Blood Cancer Group, the Structural Medicine and Thrombosis Group, and the Transfusion Medicine Group.

Those Haematology research groups belonging to the Cambridge Stem Cell Institute ( https://www.stemcells.cam.ac.uk ) moved into a brand new purpose-built facility on the Cambridge Biomedical Campus in 2019. The other Haematology groups are based at the Cambridge Institute for Medical Research, the NHS Cambridge Blood Centre and the Sanger Institute. More information can be found  here .

The department offers this full-time or part-time PhD programme of research under the individual supervision of a principal investigator based in the Department of Haematology. A full list of Haematology Principal Investigators can be found on the departmental website .

PhD students on this course are based in a research group, supported by their primary supervisor and the Postgraduate Education Committee and Postgraduate Student Committee. There is no taught or examined course work, but students are encouraged to attend research seminars on the Biomedical Campus and elsewhere in the University.

Students write a thesis, which is examined via an oral examination.

We welcome applications from postgraduates wanting to work towards a PhD, in any of the labs belonging to the Department of Haematology. Successful applicants must meet the University's minimum academic admissions criteria, and applicants are required to contact potential supervisors before submitting an application, to discuss their application and funding possibilities. A list of Haematology Principal Investigators can be found on the Department of Haematology website .

Learning Outcomes

At the end of their PhD, students should:

• have a thorough knowledge of the literature and a comprehensive understanding of scientific methods and techniques applicable to their own research;
• be able to demonstrate originality in the application of knowledge, together with a practical understanding of how research and enquiry are used to create and interpret knowledge in their field;
• have developed the ability to critically evaluate current research and research techniques and methodologies;
• have self-direction and originality in tackling and solving problems;
• be able to act autonomously in the planning and implementation of research; and
• have gained oral presentation and scientific writing skills.

Those who wish to progress to a PhD after completing an MPhil will be required to satisfy their potential supervisor, Head of Department and the Faculty Degree Committee that they have the skills and ability to achieve the higher degree.

The Postgraduate Virtual Open Day usually takes place at the end of October. It’s a great opportunity to ask questions to admissions staff and academics, explore the Colleges virtually, and to find out more about courses, the application process and funding opportunities. Visit the  Postgraduate Open Day  page for more details.

See further the  Postgraduate Admissions Events  pages for other events relating to Postgraduate study, including study fairs, visits and international events.

Key Information

3-4 years full-time, 4-7 years part-time, study mode : research, doctor of philosophy, department of haematology, course - related enquiries, application - related enquiries, course on department website, dates and deadlines:, lent 2024 (closed).

Some courses can close early. See the Deadlines page for guidance on when to apply.

Easter 2024 (Closed)

Michaelmas 2024 (closed), easter 2025, funding deadlines.

These deadlines apply to applications for courses starting in Michaelmas 2024, Lent 2025 and Easter 2025.

Similar Courses

• Medical Science (Haematology) MPhil
• Stem Cell Biology Wellcome Trust PhD
• Biological Science (Stem Cell Biology) by thesis MPhil
• Stem Cell Biology PhD
• Medical Science (CIMR) PhD

Postgraduate Admissions Office

• Admissions Statistics
• Start an Application
• Applicant Self-Service

At a glance

• Bringing a family
• Current Postgraduates
• Cambridge Students' Union (SU)

University Policy and Guidelines

Privacy Policy

Information compliance

Equality and Diversity

Terms of Study

About this site

About our website

Privacy policy

© 2024 University of Cambridge

• Contact the University
• Accessibility
• Freedom of information
• Privacy policy and cookies
• Statement on Modern Slavery
• University A-Z
• Undergraduate
• Postgraduate
• Research news
• About research at Cambridge
• Spotlight on...

University of Wisconsin Hematology Research Training Program (T32)

About our program.

The University of Wisconsin Hematology Research Training Program trains MD and PhD candidates to become independent investigators in hematology. The program is tailored to each trainee's career goals, emphasizes multidisciplinary approaches in both basic and clinical research, and provides instruction in the responsible conduct of science .

We strongly encourage underrepresented minorities to apply for pre- and post-doctoral training positions.

This program is funded by a National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) Kirschstein National Research Service Award (T32 HL07899).

How to Apply

Predoctoral positions:

• Admission to a graduate program at the University of Wisconsin-Madison
• Commitment to a laboratory within a PhD or MD-PhD program
• Must be U.S. citizen or permanent resident (green card)

Postdoctoral Positions:

• Possess MD, PhD, MD-PhD or equivalent degree
• Commitment to 2 years of training
• Payback obligation incurred during the initial 12 months of support

Send a letter of inquiry describing your career goals, your CV, and the additional materials below to:

John P. Sheehan, MD, Principal Investigator c/o David Smith 600 Highland Ave. Box: 5669 Madison, WI 53792 Email: [email protected]

Additional required application materials:

• Nominating letter from a Training Faculty member
• Brief statement of research interests (1 page)
• GRE or MCAT scores
• Undergraduate and graduate transcripts

Postdoctoral positions:

• Letters of recommendation (2)
• Brief statement of research interests/career plan (1-2 pages)

Current Fellows

Ben Anderson, PhD

Post-doctoral trainee

Mentor: Joshua Coon, PhD

Isabela Fraga De Andrade, PhD

Mentor: Bill Sugden, PhD

Trey Gilpin

Post-doctoral trainee Mentor:  Daniel Matson, MD, PhD

Corinne Moss

Pre-doctoral trainee Mentor:  Joshua Coon, PhD

Pre-doctoral trainee Mentor:   Emery Bresnick, PhD

Allison Weisnicht, MD

Mentor: Christian Capitini, MD

Graduate Success

View list of all graduates and publications (PDF)

John Sheehan, MD

Program Director

Faculty Mentors

• David J. Beebe, MD, PhD , Department of Biomedical Engineering
• Emery Bresnick, PhD , Department of Cell and Regenerative Medicine
• Jason Cantor, PhD , Department of Biochemistry
• Christian Capitini, MD , Department of Pediatrics
• Jane Churpek, MD , Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care
• Joshua Coon, PhD , Department of Biomolecular Chemistry
• Jing Fan, PhD , Department of Nutritional Sciences
• Jacques Galipeau, MD, Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care
• Jenny Gumperz, PhD , Department of Medical Microbiology and Immunology
• Anna Huttenlocher, MD , Department of Pediatrics
• Shannon Kenney, MD ,  Department of Human Oncology and Department of Medicine
• Bruce Klein, MD , Departments of Pediatrics, Medicine and Medical Microbiology and Immunology
• Bo Liu, PhD , Department of Cell and Regenerative Biology
• Ryan Mattison, MD , Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care
• Jeniel Nett, MD, PhD , Department of Medicine, Division of Infectious Disease
• Lixin Rui, PhD , Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care
• John Sheehan, MD , Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care
• Miriam Shelef, MD, PhD , Department of Medicine, Division of Rheumatology
• Igor Sluvkin, MD, PhD , Department of Pathology
• Paul Sondel, MD, PhD , Department of Pediatrics
• Owen Tamplin, PhD , Department of Cell and Regenerative Biology
• Elizabeth Wright, PhD , Department of Biochemistry
• Jing Zhang, PhD , Department of Human Oncology

Program Details

Our program emphasizes pre- and post-doctoral training in  vascular biology  and  hematopoetic stem cells and malignancy . Vascular biology is critically important for human disease, impacting such basic processes as inflammation, the immune response, hemostasis, thrombosis, and metastasis.

We have assembled expertise in cellular and molecular aspects of hemostasis, extracellular matrix biology, vasculogenesis/angiogenesis, cellular mechanisms of inflammation, the genetics of diabetes, lipoprotein metabolism, and clinical aspects if hemophilic and thrombophilic states.

Likewise, hematopoetic stem cells are important to therapeutic approaches in a variety of disease states, and the University of Wisconsin is an internationally recognized leader in embryonic stem cell biology.

We provide the multidisciplinary training required to pursue translational research opportunities, and formal training for clinical investigators.

Clinical trainees may take advantage of the NIH-funded  UW Institute for Clinical & Translational Research (ICTR) , which provides didactic training in biostatistics, epidemiology, clinical trial design, and practical skills such as scientific and grant writing.

All trainees should complete an Individual Development Plan (IDP) . This tool helps you:

• assess your current skills and strengths
• make a plan for developing skills that will help you meet both your academic and professional goals
• communicate with your advisors and mentors about your evolving goals and related skills

See also: "NIH Encourages Institutions to Develop Individual Development Plans for Graduate Students and Postdoctoral Researchers"

Research Facilities:

• Cardiovascular Research Center
• Clinical Research Services and Networks
• Carbone Cancer Center  (NCI designated)
• Wisconsin National Primate Research Center  (NIH-funded and the only of its kind in the Midwest) 
• Wisconsin Institute of Medical Research (WIMR)

Education Programs:

• Adult Hematology/Oncology Fellowship
• Pediatric Hematology-Oncology Fellowship
• UW-Madison Graduate School
• UW School of Medicine and Public Health MD-PhD program

UW Health Stem Cell Transplant and Cellular Therapy Program

Internal Medicine

• Division of Hematology & Hematologic Malignancies

PhD Graduate Programs

Many faculty members in the hematology division are training faculty in two interdisciplinary PhD graduate programs. These programs in molecular biology and biological chemistry provide a cross-disciplinary, collaborative training environment that enables students to experience a wide-ranging selection of research opportunities representing 11 departments at the University of Utah. Each program is distinct in its core curriculum and requirements.

The programs allow students to experience a broad scientific education, yet tailor their training to their specific interests. Students will participate in cutting-edge research mentored by world-class scientists. In addition, the programs provide the thorough training necessary to become a creative and analytical thinker essential of a successful career in science. 

Read a full description of the programs .

Training opportunities exist in these research programs. To get more information on research opportunities, you can either contact a specific faculty member or contact us .

Haematology MPhil/PhD

London, Bloomsbury

When you study a haematology research degree at the UCL Cancer Institute, you join a supportive and intellectually rigorous environment to develop your research skills, subject knowledge, and critical review abilities. Our excellent facilities, supervision and training opportunities prepare you for careers in academia, industry, business, biomedicine, and healthcare.

UK tuition fees (2024/25)

Overseas tuition fees (2024/25), programme starts, applications accepted.

• Entry requirements

A minimum of an upper second-class UK Bachelor’s degree in a relevant discipline or an overseas qualification of an equivalent standard.

The English language level for this programme is: Level 3

UCL Pre-Master's and Pre-sessional English courses are for international students who are aiming to study for a postgraduate degree at UCL. The courses will develop your academic English and academic skills required to succeed at postgraduate level.

Further information can be found on our English language requirements page.

Equivalent qualifications

Country-specific information, including details of when UCL representatives are visiting your part of the world, can be obtained from the International Students website .

International applicants can find out the equivalent qualification for their country by selecting from the list below. Please note that the equivalency will correspond to the broad UK degree classification stated on this page (e.g. upper second-class). Where a specific overall percentage is required in the UK qualification, the international equivalency will be higher than that stated below. Please contact Graduate Admissions should you require further advice.

About this degree

Haematology is one of five research departments within the Cancer Institute. It covers areas such as leukaemia biology, stem cell transplantation, transplantation immunology, tumour Immunology, cellular and gene therapy, multiple myeloma, and tumour immunodynamics.

You will develop your research hypothesis with your supervisors, and undertake novel laboratory, bioinformatic or clinical research as part of their research team. You will be supported by a supervisory team including your principal supervisor, and a thesis committee which comprises a secondary supervisor and one to three committee members.

Knowledge and skills development is a core priority of our programme. As well as UCL's Doctoral Skills Programme, the Cancer Institute runs a compulsory first-year training programme that will improve your research skills and provide networking opportunities.

This Haematology PhD programme is based in London and is available on a full-time or part-time basis.

Who this course is for

We welcome high achieving students who want to join a world-class centre to do haematology research. Students come from all over the world and from a wide range of backgrounds, including clinicians, scientists and anyone interested in haematology.

What this course will give you

• A unique opportunity to work in a collaborative research environment that spans basic research, translational medicine, and clinical applications.
• Close links with associated clinical trials facilities, experimental cancer medicine centre, biobanking facilities and associated partners and hospitals in London such as the Royal Free Hospital, UCLH, and Cancer Research UK and the Crick Institute.
• Skills development, including bench and technical skills, critical evaluation of scientific literature, experimental planning and design, interpretation of data results, presentation/public speaking skills, time and project management, working within a team, working independently, and writing for various audiences.

The foundation of your career

Our excellent facilities, supervision and training opportunities prepare you for future careers in academia, industry, business, biomedicine, and healthcare.

Employability

Graduates go on to academic posts at institutions including universities around the world. Other career pathways include laboratory management, research, industry, clinical trials co-ordination, scientific writing and editing, sales and consulting.

Some go onto further medical training or clinical posts.

The programme is designed to give you networking opportunities throughout your period of study.

These include weekly internal divisional seminars, a weekly external speaker seminar and reception, and student poster sessions. You will also attend the Annual Cancer Institute Conference, as well as national and international research conferences, and academic careers days. 

On graduating, you will be able to join the Institute’s alumni network on LinkedIn.

Teaching and learning

Most of your research will be carried out independently. There will also be a series of training requirements that you will need to complete in the early stages of the programme.

All research students attend a training programme on lab skills from January to July of the the first year. This covers:

• Human Tissue Act and the Biobank
• Tissue Preparation and Staining
• Basics of Proteomics
• Principles of Good Clinical Lab Practice
• Clinical Trial Design and Regulation
• In vivo Study Design and Regulation
• Preclinical Radiotherapy
• Single Cell Analysis.

Your first milestone will be to upgrade from MPhil to the PhD degree. For this, you will submit and present a report. In your final year, you submit a thesis covering your research and discuss this at a formal interview known as a viva examination.

Most of your time will be spent conducting independent research, alongside regular meetings with your supervisory team and completing your training requirements. We also encourage you to attend relevant research events at UCL and elsewhere.

Research areas and structure

• Acute myeloid Leukaemia and multiple myeloma
• Cellular and gene therapy
• Dendritic cell immunotherapy
• Immune regulation and tumour immunotherapy
• Molecular cytogenetics
• Stem cell transplantation and cellular immunotherapy
• Transplantation immunology
• Translational immunotherapy

Research environment

UCL is a top-rated university in the UK for research strength in the Research Excellence Framework (REF 2021). Our scientists have an international reputation for leading basic, translational, and clinical cancer research and the Cancer Institute is uniquely positioned to leverage the multidisciplinary nature of UCL by engaging a range of disciplines to transform cancer research.

You will join a community of over 300 research scientists and 120 research students within the Cancer Institute. Our combination of fundamental cancer research, clinical links with UCLH, and the Royal Free Hospitals, and collaborative links with the Crick Institute and Cancer Research UK, make the Cancer Institute an exciting environment for basic and translational research into cancer.

The Department of Haematology has a range of research groups, including:

• Dendritic Cell Immunotherapy
• Leukaemia Biology
• Signal Transduction and Drug Resistance in Leuk...
• Stem Cell Transplantation & Cellular Immunotherapy
• Translational Immunotherapy
• Transplantation Immunology
• Tumour Immunology, Cellular and Gene Therapy
• Biology of Adult Lymphoblastic Leukaemia and Oncolytic Virus Therapy
• Immune Regulation and Tumour Immunotherapy Lab
• Multiple Myeloma Lab
• Tumour Immunodynamics Research Group.

We encourage you to become part of the community and to present and discuss your work at research team meetings, Institute Research in Progress talks, the annual Cancer Institute conference and Research Student poster day. You will also be encouraged to present at relevant international conferences and, where appropriate, to contribute towards scientific publications in your field.

The duration of a full-time research degree is usually three to four years. You register initially for the MPhil degree.

Within three months of joining the programme, you will be expected to agree the basic structure of your research project with your supervisor, along with the appropriate research methods and a realistic plan of your work. You will produce and submit a detailed outline of your proposed research to your supervisor and thesis committee for comments and feedback.

You will then undertake this project as part of your supervisor’s research team. Training workshops at the Cancer Institute will run from January to October.

In your second year, you continue to explore your research hypothesis and to collect and analyse novel data. You will also be expected to upgrade from MPhil to PhD.

To complete your upgrade, you submit a report summarising your research to date, and present and answer questions about this work at a viva voce examination. You also present your research to the department at a Research in Progress seminar.

In your third year, you complete your data collection and analysis, and prepare your thesis. You will also be encouraged to present your findings at an international conference or annual Cancer Institute conference.

Following the third year, you may be eligible for a year of 'completing research status' to complete your thesis and to take your viva examination.

The duration of a part-time research degree is usually five years. You register initially for the MPhil degree.

Within five months of joining the programme, you are expected to agree the basic structure of your research project with your supervisor, along with an appropriate research method and a realistic plan of your work. You will produce and submit a detailed outline of your proposed research to your supervisor and thesis committee for comments and feedback.

In your second and third years (18-36 months), you will continue to explore your research hypothesis and collect and analyse novel data. You will also be expected to upgrade from an MPhil to a PhD.

To complete your upgrade, you submit a report summarising your research to date, and then present and answer questions about this work at a viva voce examination. You also present your research to the department at a Research in Progress seminar.

In your fourth and fifth years, you complete your data collection and analysis, and prepare your thesis. You will also be encouraged to present your findings at an international conference or annual Cancer Institute conference.

Following the fifth year, you may be eligible to transfer to 'completing research status' for two years to complete your thesis writing and to undertake your viva examination.

Accessibility

Details of the accessibility of UCL buildings can be obtained from AccessAble accessable.co.uk . Further information can also be obtained from the UCL Student Support and Wellbeing team .

Fees and funding

Fees for this course.

The tuition fees shown are for the year indicated above. Fees for subsequent years may increase or otherwise vary. Where the programme is offered on a flexible/modular basis, fees are charged pro-rata to the appropriate full-time Master's fee taken in an academic session. Further information on fee status, fee increases and the fee schedule can be viewed on the UCL Students website: ucl.ac.uk/students/fees .

Additional costs

Students receive a free printing allowance each year and pay for any additional printing ( see details ). You may also face additional expenses if you attend conferences. The cost depends on the location, exchange rates, and the price of travel and accommodation, but this may be between £200 and £500 per event, based on typical events / destinations attended by recent students. The Cancer Institute provides two competitive travel scholarships each year to support research students attending training workshops or international conferences.

If you are doing a wet lab project, there may be an Additional Fee Element (AFE, also known as bench fees). This is an additional annual cost related to consumables, equipment or materials based on your individual project. This is payable by your sponsor, or yourself, if self-funding. These additional costs depend on the project and will be the same for home and overseas students.

The Cancer Institute provides some competitive travel scholarships to support research students attending training workshops or international conferences.

For more information on additional costs for prospective students please go to our estimated cost of essential expenditure at Accommodation and living costs .

Funding your studies

Annual CRUK funded clinical fellowships and non-clinical PhD studentships are available. Please check the Cancer Institute website for details. Other funded studentships will also be advertised on the Institute website as they become available. Some of our students seek funding from their home country or cancer charities.

For a comprehensive list of the funding opportunities available at UCL, including funding relevant to your nationality, please visit the Scholarships and Funding website .

Your first steps are to find a supervisor and funding before applying. You should check both the UCL and the Cancer Institute's studentships to apply for specific projects with grants. You can also reach out directly to any potential supervisor, particularly if you have funding in place from another source. You can identify Principal Investigators via the Cancer Institute website and research them individually. If you need help, please see applying for graduate research study or contact the Admissions Tutor on [email protected].

You can apply at any time. However, there are three entry points over the year. Deadlines and start dates are usually dictated by funding arrangements and supervisor availability, so discuss this with your supervisors.

Please note that you may submit applications for a maximum of two graduate programmes (or one application for the Law LLM) in any application cycle.

Choose your programme

Please read the Application Guidance before proceeding with your application.

Year of entry: 2024-2025

Got questions get in touch.

Cancer Institute

[email protected]

UCL is regulated by the Office for Students .

Prospective Students Graduate

• Graduate degrees
• Taught degrees
• Taught Degrees
• Applying for Graduate Taught Study at UCL
• Research degrees
• Research Degrees
• Funded Research Opportunities
• Doctoral School
• Funded Doctoral Training Programmes
• Applying for Graduate Research Study at UCL
• Teacher training
• Teacher Training
• Early Years PGCE programmes
• Primary PGCE programmes
• Secondary PGCE programmes
• Further Education PGCE programme
• How to apply
• The IOE approach
• Teacher training in the heart of London
• Why choose UCL?
• Entrepreneurship
• Inspiring facilities and resources
• Careers and employability
• Your global alumni community
• Your wellbeing
• Postgraduate Students' Association
• Your life in London
• Accommodation
• Funding your Master's

Hematology Faculty

Division chief.

Ann Mullally, MD

Physician-scientist studying myeloid malignancies.

Major interests are myeloproliferative neoplasms (MPN) and clonal hematopoiesis (CH) .

Active areas of research include (i) biology & therapy of mutant calreticulin, (ii) JAK2V617F biology, (iii) clonal expansion of MPN stem cells, (iv) immunological approaches to target MPN.

Steven E. Artandi, MD, PhD

Jerome and Daisy Low Gilbert Professor,

Director of Stanford Cancer Institute

Understanding the early stages of cancer development

Mechanisms in dyskeratosis congenita and other degenerative diseases

Telomerase function inside human stem cells and cancer cells

Caroline Bérubé, MD

Clinical Associate Professor

Medical Director Outpatient Anticoagulation Clinic

General hematology

Specific interest in clinical thrombosis and hemostasis, management of anticoagulation, hemophilia, pregnancy-related hematologic conditions, immune thrombocytopenia, and anemia.

Ami Bhatt, MD, PhD

My laboratory uses molecular, micro- and computational biology techniques to dissect the role of the microbiota in hematological disorders.

We hope to target vulnerabilities in hematological disorders characterizing and modifying the human microbiota, thereby improving patient outcomes.

Linda M. Boxer, MD, PhD

Stanley McCormick Memorial Professor

Vice Dean, School of Medicine

Roni Brar, MD

Clinical Assistant Professor

Optimizing clinical evaluation for patients with benign and malignant hematologic conditions.

Novel clinical trials for acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and other hematologic malignancies.

Implementing personalized genomic medicine with high impact results into the clinic. 

May Chien, MD

Gene therapy for hemophilia and understanding the pathophysiology of immune thrombocytopenia. 

Robert Diep, MD

Benign Hematology Consult Core

Tamara Dunn, MD

Program Director, Hematology Fellowship Program

Associate Chair of Diversity and Inclusion in the Department of Medicine

Bita Fakhri, MD, MPH

Assistant Professor

My research focus is on the development of novel therapies for chronic lymphocytic leukemia/small lymphocytic lymphoma, with a particular interest in cell-based therapies (bispecific T cell engagers), and new targets/pathways (BTK degraders and ROR1). My other area of focus is understanding the predictive and prognostic value of pathogenic mutations commonly seen in CLL/SLL and their association with clinical behavior. Last but not least, I have a genuine interest in clinical trial equity, and identifying the surmountable barriers to clinical trial enrollment among underserved and marginalized populations.

Lawrence Tim Goodnough, MD

Professor, Pathology & Medicine

Oversees and supervises rotation of Hematology/ Oncology fellows in Transfusion Service

Director, Transfusion Medicine Fellowship Program

Associate Medical Director, Stanford Blood Center

Jason R. Gotlib, MD

Phase I/II trial evaluation of novel therapies for myelodysplastic syndromes, acute myelogenous leukemia, chronic myelogenous leukemia, and chronic myeloproliferative disorders (MPDs, eg. polycythemia vera, essential thrombocythemia, primary myelofibrosis, hypereosinophilic syndromes, and systemic mastocytosis) Translational research collaborations to interrogate the molecular basis of CML and chronic MPDs MPDs Associate Director, Stanford Myelodysplastic Syndromes Center Director, Hematology Division Tissue Bank Director, Med 8, Inpatient Hematology Service 

Peter L. Greenberg, MD

Professor, Emeritus (Active)  

As Director of the Stanford MDS Center, Dr Greenberg has an active clinical practice focusing on the evaluation and treatment of myelodysplastic syndromes (MDS) and clonal myeloid disorders. His clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and is now evaluating the impact of molecular mutations on this risk-based prognostic system. He is Chair of the NCCN Practice Guidelines Panel for MDS.

More research info

David Iberri, MD

Caring for patients with multiple myeloma, Waldenström macroglobulinemia, and related plasma-cell and lymphoid disorders. Using novel biomarkers to personalize therapy and predict treatment response

Participating in clinical trials to advance the care of patients with a variety of hematologic malignancies including MDS, AML, and CLL.

Calvin J. Kuo, MD, PhD

Maureen Lyles D'Ambrogio Professor

Organoid modeling of cancer

Intestinal stem cell biology

Blood-brain barrier vascular biology

Lawrence L.K. Leung, MD

Thrombin-activatable carboxypeptidase B2 in the crosstalk between coagulation, thrombosis, inflammation and innate immunity

Thrombin cleavage of osteopontin in cancer biology

Chemerin and insulin resistance

Epidemiology Center in Research and Information (ERIC) in support of genomics at Palo Alto VA

Michaela Liedtke, MD

Associate Professor

Director, Stanford Adolescent and Young Adult (AYA) Cancer Program

Design of clinical trials using new therapeutic strategies and experimental therapeutics for multiple myeloma, amyloidosis and acute lymphoblastic leukemia. Translational research collaborations to investigate the pathophysiology of amyloidosis. Development of a program addressing the unique needs of adolescents and young adults with cancer.

Amyloid Center

Stanford Adolescent and Young Adult Cancer (SAYAC) Program

Sydney X. Lu, MD, PhD

Assistant Professor of Medicine

Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of: 1) normal and pathologic immunity and immunotherapy 2) cancer biology 3) normal and malignant hematopoiesis

Ravi Majeti, MD, PhD

RZ Cao Professor of Medicine

Molecular characterization of human acute myeloid leukemia stem cells and their pathogenesis using bioinformatics, genomics, microfluidics, flow cytometry, and xenotransplantation assays in mice Development of novel therapeutic monoclonal antibodies directed against human acute myeloid leukemia stem cell surface antigens Investigation of normal human hematopoiesis and hematopoietic stem cells using similar techniques.

Jim Malone, MD

Benign Hematology consult service

Gabriel Mannis, MD

My research focuses on the development of novel therapies for acute leukemia, with a particular interest in immunotherapy, targeted agents, and predictive biomarkers as a means to improve outcomes and quality of life for patients with hematologic malignancies.

Beth A. Martin, MD

Clinical Assistant Professor 

Clinical interests include the histiocytoses including HLH/MAS, autoimmune hematology including T-LGL, AIHA, and Castleman.  Educational interests include physical diagnosis, clinical decision-making and communication under desperate circumstances, and chemotherapy.  My research focuses on HLH.

Bruno Medeiros, MD

Affiliated Professor

My research interests focus on the experimental therapeutics of Acute Myeloid Leukemia (AML) with the ultimate goal of improving our understanding of the genomic abnormalities responsible for leukemogenesis and how these abnormalities can be exploited therapeutically. It also includes the development and incorporation of novel agents into the treatment regimens for young and older patients with AML and those with acute leukemia secondary to antecedent hematologic disorders.  

Beverly S. Mitchell, MD

George E. Becker Professor  

Role of nucleotides in regulating nucleolar organization, function and cell proliferation

Novel therapies for acute leukemia with correlative studies

Function of a novel DNA repair protein with ubiquitin ligase activity

Elizabeth A. Price, MD, MPH

Clinical and laboratory characterization of unexplained anemia of aging Development of clinical protocol evaluating hematologic and functional response to interventions in unexplained anemia of aging

Tait Shanafelt, MD

Jeanie and Stew Ritchie Professor

Determining why people develop CLL and, its precursor condition, monoclonal B-cell lymphocytosis (MBL). 

Identifying molecular characteristics and prognostic tools that predict which CLL patients will experience a more aggressive disease course. 

Identification and testing of new compounds for treating CLL. 

William Shomali, MD

Dr. William Shomali is a Clinical Assistant Professor in Hematology and his goal is to study novel targeted therapies in patients with blood cancers, with a focus on myeloproliferative neoplasms and myelodysplastic syndromes.  

James L. Zehnder, MD

Clinical and laboratory investigation of thrombosis and bleeding disorders Molecular diagnostic testing for inherited thrombophilia and hematololymphoid malignancy

Tian Zhang, MD, PhD

Tian Yi Zhang is an Assistant Professor of Medicine in Hematology and a member of Stanford Cancer Institute. She earned her MD and PhD from University of Utah. Dr. Zhang completed her Hematology and Oncology Fellowship at Stanford and is a board-certified hematologist. While at Stanford, she completed post-doctoral training in the laboratory of Ravi Majeti, where she investigated why patients with acute myeloid leukemia (AML) develop bone marrow failure. Dr. Zhang is the recipient of the ASH RTAF award, the A.P. Giannini Fellowship award, SCI fellowship award, and the NIH T32 Hematology Training grant. She was recently awarded the American Cancer Society-Stanford Cancer Institute Pilot Grant to study immune repertoire perturbations in IDH mutated AML. Dr. Zhang’s current research on AML induced bone marrow failure is funded by the National Cancer Institute (NCI) Career Development Award (K08). Her clinical focus includes the comprehensive care of patients with AML and other myeloid malignancies. She hopes to use the cutting edge science uniquely available at Stanford to develop a robust translational medicine program in the Division of Hematology.

• For Physicians
• Apheresis/Transfusion Service
• News and Media
• Selected Publications
• Informatics
• Selected Publication
• Molecular Test Menu
• Tumor Profiling
• Seasonal Reports
• 2023 Seasonal Reports
• Virology Newsletter
• 2022 Seasonal Reports
• 2021 Seasonal Reports
• 2020 Seasonal Reports
• 2019 Seasonal Reports
• 2018 Reports
• 2017 Reports
• 2016 Reports
• 2015 Reports
• 2014 Reports
• 2013 Reports
• 2012 Reports
• 2011 Reports
• 2010 Reports
• 2009 Reports
• 2008-06 Reports
• News & Recognition
• Clinical Testing and Research Samples
• Publications
• Research Faculty Laboratory Sites
• Overview of the Facility
• Faculty Specialty Search
• Physician Scientist Pathway (PSP)
• Faculty & Residents
• Clinical Informatics
• Clinical Chemistry
• Microbiology
• Molecular Genetic Pathology
• Graduate & Postdoctoral
• Medical Students
• Medical Technologist Clinical Rotations
• Administration and Staff

INFORMATION FOR

• Residents & Fellows
• Researchers

Research Training in Immunohematology & Transfusion Medicine

The Department of Laboratory Medicine at the Yale School of Medicine offers 2-3 years of structured post-doctoral research training in the broad field of Immunohematology to MDs, MD/PhDs, and PhDs interested in long term investigative careers in academia or elsewhere. This NIH-funded NRSA (T32) program is designed to provide the basic science, translational, and clinical research skills needed for individuals to become successful clinician-scientists and scientists.

The major areas of focus are:

• Stem Cells/Hematopoiesis
• Transfusion Medicine
• Host-Pathogen Interactions
• Vascular Biology/Transplantation
• Biomedical Engineering.

Trainees must meet the criteria for support on an NIH NRSA: a citizen or a non-citizen national of the United States or have been lawfully admitted for permanent residence at the time of appointment.

Applications are accepted throughout the year. For applications and inquiries, please follow the instructions under “ Apply ”.

Current Trainees

Clinical Fellow

Sarah N. Dudgeon, MPH View Full Profile

Amos Espinosa View Full Profile

Clinical Fellow; Instructor, Pathology & Laboratory Medicine

Postdoctoral Fellow

Postdoctoral Associate

Our Graduates

We are very proud of the graduates of our physician-scientist and scientist training programs in the Department. Below we list just a few of these individuals:

• Terrence Geiger, MD, PhD - Member, St. Jude Children's Research Hospital; Director Clinical Pathology; Senior Vice President and Deputy Director for Academic and Biomedical Operations
• Li Chai, MD - Associate Professor of Pathology, Brigham & Women's Hospital/Harvard; Associate Director of Transfusion Medicine
• Erica Herzog, MD, PhD - Associate Professor of Internal Medicine (Pulmonary); Director, Translational Lung Research Program, Yale
• Joseph P. Mathew, MD - Professor and Chair of Anesthesiology, Duke University
• Tonya Colpitts, PhD - Associate Director of Virology, Moderna
• David Persing, MD, PhD - Executive Vice President, Chief Medical & Technology Officer, Cepheid Corporation
• David Leitenberg, MD, PhD -Associate Professor Pathology, George Washington University
• Mark Velleca, MD, PhD - Chief Executive Officer, StrideBio
• Jonathan Genzen, MD, PhD - Associate Professor of Pathology, University of Utah
• Mandar Kulkarni, PhD - Chief Technical Officer, Cancer Genetics
• Michael Hodsdon, MD, PhD - Medical Fellow, Eli Lilly
• Stephanie Eisenbarth, MD, PhD - Associate Professor of Laboratory Medicine and Immunobiology, Yale University
• Kevin Nickerson, PhD - Research Assistant Professor of Immunology, University of Pittsburgh
• Tore Eid, MD, PhD - Assistant Professor of Laboratory Medicine and Cellular & Molecular Physiology, Yale University
• Richard Torres, MD, MSc - Associate Professor of Laboratory Medicine, Yale University
• Susan Fink, MD, PhD - Assistant Professor of Laboratory Medicine, University of Washington
• Daniel Jane-Wit, MD, PhD - Assistant Professor of Internal Medicine (Cardiology), Yale
• Alex Ryder, MD, PhD - Medical Director at Spectra Laboratories, Inc.
• Ellen Foxman, MD, PhD - Assistant Professor of Laboratory Medicine, Yale
• Maudry Laurent-Rolle, MD, PhD - Assistant Professor, Infectious Diseases, Yale University
• Cheyne Kurokawa, PhD - Senior Scientist, AstraZeneca
• Susanna Curtis, MD, PhD - Assistant Professor, Montefiore Medical Center Assistant Director, Sickle Cell Program for Adults, Montefiore
• Nadia Ayala-Lopez, PhD - Fellow, Clinical Chemistry, Johns Hopkins University
• Vanessa Scanlon, PhD - Instructor, Dept. of Laboratory Medicine, Yale University
• Raisa Balbuena-Merle, MD - Assistant Professor, Dept. of Laboratory Medicine, Yale University
• James Zachary Porterfield, MD, PhD - Assistant Professor, Microbiology Immunology and Molecular Genetics, University of Kentucky
• Manuel K. Rausch, PhD - Assistant Professor, Biomedical Engineering, University of Texas at Austin
• David R. Gibb, MD, PhD - Associate Pathologist, Cedars-Sinai, Los Angeles, CA.

FCS News: Core Ventures to become a part of McKesson’s The US Oncology Network (The Network) Click to Learn More

• Find a Clinical Trial
• Find a Physician
• Find a Location
• Cancers We Treat
• Bispecific Therapy
• Chemotherapy
• Clinical Trials
• Immunotherapy
• Infusion Therapy
• Radiation Treatment
• Radiotherapy
• Care Coordination
• FCS Foundation
• Genetic Screening & Testing
• Insurance & Financial Navigation
• Nutrition & Wellness
• Supportive Care
• Patient Education
• Patient Education Videos
• Rx To Go (Pharmacy)
• Your First Visit
• Visitor Information
• Patient Stories
• Patient Experience Portal
• Supporting a Loved One
• Why Choose FCS
• Refer a Patient
• Clinical Research Associates
• FCS Hematology Oncology Review
• Insurance & Financial Counseling
• Radiology Non-FCS Scans
• Current Opportunities
• Case Studies
• Our Partners
• Accreditations
• Locations by County
• Mission Vision Values
• Executive and Senior Management
• Physician Leadership
• Clinical Trials Team
• Gynecologic Oncology
• Radiation Oncology
• News & Articles
• FCS Publications

Wenqing Zhang, MD, PhD

Dr. Zhang is a board-certified medical oncologist and hematologist with Florida Cancer Specialists & Research Institute in Pinellas and Citrus counties. He specializes in the treatment of all cancer types and blood disorders, with a specialized focus on breast cancer, lung cancer, and lymphoma.

After receiving his medical degree from Xinxiang Medical College in China, Wenqing Zhang, MD, went on to earn both a master’s and a doctorate in Medical Science from Beijing Medical University. He completed Internal Medicine residency training at Albert Einstein College of Medicine in Bronx, NY and a fellowship in Hematology/Oncology at the University of Louisville James Graham Brown Cancer Center in Louisville, KY.

Dr. Zhang joined Florida Cancer Specialists in 2022.  Previously, he provided medical oncology care in academic and private practice settings and, most recently, served as Director of the Breast Cancer Program at St. Luke’s University Health Network in Pennsylvania.

In addition to treating oncology patients for many years, Dr. Zhang is actively involved in cancer research, serving as an investigator and sub-investigator for clinical trial studies. He has published numerous articles in peer-reviewed journals including the Chinese Journal of Clinical Oncology, Chinese Journal of Hematology, RNA and Pathology and Laboratory Medicine International.

In his spare time, he enjoys hiking, outdoor activities and martial arts.

• Medical Oncology

Medical School

Beijing Medical University/Peking University, Beijing, China

Internal Medicine – Albert Einstein College of Medicine, Bronx, NY

Hematology/Oncology – James Graham Brown Cancer Center/University of Louisville, Louisville, KY

Board Certification

Bone Marrow Biopsy

Professional Affiliations

American Society of Hematology American Society of Clinical Oncology

You must have javascript enabled to use this website.

Melissa Anne Faith , PhD

Pediatric psychology.

• Johns Hopkins School of Medicine Faculty
• All Children's Specialty Physicians

9 Insurances Accepted

Primary academic title.

Assistant Professor of Psychiatry and Behavioral Sciences

Dr. Faith is a clinical pediatric psychologist specializing in hematology/oncology at Johns Hopkins All Children’s Hospital. She received her master’s and doctorate degrees in clinical psychology from the University of Arkansas, completed a predoctoral internship in clinical child psychology at the University of Mississippi Medical Center and completed a postdoctoral fellowship in clinical psychology with an emphasis in pediatric hematology and oncology at the University of Oklahoma Health Sciences Center. Dr. Faith’s research interests include disseminating evidence-based interventions in large medical and community centers (e.g., motivational interviewing) as well as emotion socialization, social adjustment, and sibling adjustment during and following childhood chronic illness.   

• 501 6th Avenue South , Saint Petersburg , FL 33701
• phone: 727-898-7451
• fax: 727-898-7452

University of Oklahoma Health Sciences Center

University of arkansas for medical sciences, board certifications, clinical psychology.

• Aetna Behavioral Health
• Avmed (Commercial)
• BCBS FL (Commercial)
• Evolutions (Commercial)
• Humana Behavior Health
• Multiplan (Commercial)
• United Behavioral Health (Optum)
• WPS TriCare East (Commercial)

• ASH Foundation
• Log in or create an account
• Publications
• Diversity Equity and Inclusion
• Global Initiatives
• American Society of Hematology
• Resources for Medical Students and Residents
• Why I Chose Hematology
• Edward Benz Jr., MD, PhD: Why I Chose Hematology
• Agenda for Nematology Research
• Precision Medicine
• Genome Editing and Gene Therapy
• Immunologic Treatment
• Research Support and Funding

Edward Benz Jr., MD, PhD: Why I Chose Hematology

Q: How did you become interested in the field of hematology? Academia in particular?

A: I became interested in academic medicine before becoming interested in hematology. It started in high school when I got in an argument with a nun about how many chromosomes man has. That got me interested in DNA and then molecular biology (MB). I was very interested in MB research in college and wanted to pursue patient research in MB, which was very new in the 70s. I became interested in hematology because of a presentation by  David Nathan  (a past president of the American Society of Hematology). I realized hematology was the only field that would allow me to use MB research to study human disease. It was virtually impossible in other areas, except in hematology because you can work directly with patient blood cells.

Q: Why do you think it is important for people to get involved in this field?

A: Because hematologists are responsible for treating patients with many major conditions that cause illness and death. For example, one third of patients with cancer actually die of blood-clotting related to their cancer. Also, it is still the specialty of medicine where the newest discoveries in science first get applied to human disease.

Q: In your experience, what is the most difficult or challenging aspect of becoming a hematologist in the United States?

A: It's not that challenging to become one - you have to go to medical school, get into a good residency program, then be accepted into a fellowship - those hurdles are true for every specialty in medicine. The challenge in being a hematologist, unless you're also an oncologist, is the reimbursement scheme, which makes it difficult to be in private practice in hematology. If you're interested in working purely in hematology, you will find yourself working at an academic center. If you want to work in private practice by being a hematologist/oncologist, the oncology part of your practice will overwhelm hematology and make it hard for you to focus on hematology and keep up with the research.

Hematology is a broad discipline so you have to master many different subtopics of hematology - for example, in leukemia, bone marrow failure, transfusion medicine, etc. So, you have to be able to think broadly as well as deeply.

Q: How do you feel advances in technology (recent or past) have helped you along the way, be it in your studies or in general practice?

A: Advances in scientific technology have been incredibly helpful for diagnosis and treatment of hematologic disorders. We can now give growth factors to help patients replace the loss of red and white blood cells who used to need transfusion. We can replace clotting factors in hemophilia. We can diagnose leukemia to a level of precision that we can customize therapies in a more advanced way than most other areas of medicine.

Q: What do you find to be most rewarding about a career in hematology?

A: You can do good because you're taking care of patients and helping them with conditions that really require specialized knowledge. And you can do research that is still on the very cutting edge of science but still very relevant to the needs of your patients. Hematologists are the nicest docs out there.

Q: Finally, what advice might you have for a younger person who will be pursuing a career in this field?

A: You want to be sure that you're achieving academically. You need a very strong background in science, and be sure that you're learning great communication skills so you can be both a physician and a scientist. Hematologists must be adept at all of the things that make you a caring physician but also very well prepared scientifically because it is a science-driven discipline.

The beautiful thing about hematology is that there are so many ways where you can be of use to patients and study something truly fascinating. If you're a good hematologist, you'll have unique knowledge and the ability to help patients that no one else can help, and you can still be a very accomplished researcher.

After my second year of medical school I took a year off to try to apply the brand new techniques of MB to study a form of inherited anemia called thalassemia. I was trying to do something that no one has ever tried to do before. At 49 weeks out of my 52 weeks in the lab, I had nothing - nothing worked. I paid a visit to a professor at the Massachusetts Institute of Technology (across the river), and during the course of that conversation we realized I had the right question to answer, and he had the right system to answer it. In the next three weeks we were able to generate data that really launched my career and today remains one of my most important research contributions. Lesson: You can feel like you're beating your head against the wall, but you're only one conversation away from something really special. I had been contemplating quitting, but my mentor wouldn't let me do it. Find people you feel you can really trust with your future.

Thalassemia patients don't make hemoglogbin. In those days we knew genetic diseases could result in making abnormal proteins that functioned in the wrong way. No one had a way of understanding diseases in which you failed to regulate the protein.

We were the first at the National Institutes of Health to isolate and express human messenger RNA (ribonucleic acid) and show that it was a defect in that messenger RNA in these patients that explained why they had the disease. It was among the first applications of MB to explain human disease. The other lab that deserves credit is the lab of Art Nienhuis who worked with French Anderson. I worked with Bernie Forget - they were our senior mentors.

Research is a long run for a short slide.

Related Content

Find inspiration from hematologists working in a number of areas by learning more about what interested them in the field, current challenges, and advice for future hematologists.

You can also search by physician, practice, or hospital name

• Saint Petersburg

Find the Best Hematologist near you in Saint Petersburg, FL

Saint Petersburg, FL has 91 Hematologist results with an average of 36 years of experience and a total of 656 reviews . Need help deciding? Explore feedback from real patients, what awards they've won, and much more to help you choose. Currently, 63 providers have noted they are accepting new patients .

Provider Gender

Years Experience

Profile Type

Dr. Kamran Darabi, MD

Hematology, Internal Medicine, Oncology, Pathology

24 Years Experience

24 Years Exp

Dr. Sara Karjoo, MD

Hematology, Pediatric Gastroenterology, Pediatrics

17 Years Experience

17 Years Exp

Dr. Cassandra D. Josephson, MD

Pediatric Hematology-Oncology, Hematology, Pediatrics

28 Years Experience

28 Years Exp

Dr. Robert Thomas Slockett, MD

Pathology, Hematology

42 Years Experience

42 Years Exp

Dr. Thomas Karl Barton, MD

48 Years Experience

48 Years Exp

Dr. Michael Diaz, MD

Oncology, Hematology

25 Years Experience

25 Years Exp

Dr. Ananth Iyer, MD

Hematology, Oncology

Dr. Joseph R. Mace, MD

31 Years Experience

31 Years Exp

Dr. Carmelo Blanquicett, MD, PHD, FACP

Dr. Vu Tran Ho, MD

26 Years Experience

26 Years Exp

Dr. Lane Douglas Ziegler, DO

39 Years Experience

39 Years Exp

Dr. Nuruddin Jooma, MD

Dr. Jennifer Beck Dean, MD

Dr. Don D. Luong, MD

22 Years Experience

22 Years Exp

Dr. Kerry E. Chamberlain, DO

Dr. Jose Alemar, MD

Oncology, Hematology, Internal Medicine

Dr. Gregoire Bergier, MD

29 Years Experience

29 Years Exp

Dr. Sireesha Datla, MD

Dr. Kevin Owen Mcnerney

Dr. Jennifer Lynne Giglia, MD

Dr. Christopher George, MD

Dr. Damian Abel Laber, MD

32 Years Experience

32 Years Exp

Find Other Specialists In Your City

• Dentists, Saint Petersburg, FL
• Dermatologists, Saint Petersburg, FL
• Gastroenterologists, Saint Petersburg, FL
• Obstetrician-Gynecologists, Saint Petersburg, FL
• Ophthalmologists, Saint Petersburg, FL
• Pediatricians, Saint Petersburg, FL
• Psychiatrists, Saint Petersburg, FL
• More Specialties

We know that finding the right doctor or provider is important to your health. That’s why we want to ensure you have confidence in the provider profiles and listings you see on WebMD Care. Our provider data is sourced from the physicians themselves as well as publicly available databases. Any doctor or provider who claims their profile by verifying themselves can update their information and provide additional data on their specialties, education, accepted insurances, conditions they treat, and procedures they perform.

All the physician and provider reviews on WebMD Care are provided by users just like you. Knowing these reviews provide insight into how other patients feel about a doctor, we maintain internal policies and protocols to ensure the quality and accuracy of all reviews. Providers are not able to remove or modify reviews on their own. Reviews can only be removed after an internal review by our customer service team.

We value your input and encourage you to reach out to our support team if you encounter any issues.

• • Allergists & Immunologists
• • Addiction Psychiatrist
• • Bariatric Surgeons
• • Cardiologists
• • Chiropractors
• • Dermatologists
• • Ear, Nose & Throat Doctors
• • Endocrinologists
• • Family Practitioners
• • Gastroenterologists
• • Hematologists
• • Internists
• • Neurologists
• • Obstetrics & Gynecology
• • Oncologists
• • Ophthalmologists
• • Optometrist
• • Orthopedic Surgeons
• • Pain Medicine Doctors
• • Pediatricians
• • Plastic Surgeons
• • Podiatrist
• • Primary Care Doctors
• • Psychiatrists
• • Psychologists
• • Rheumatologists
• • Urologists
• • Vascular Surgeons
• Internal Medicine
• Cardiovascular Disease
• Family Medicine
• Gastroenterology
• TMS Transcranial Magnetic Stimulation
• Ketamine Infusion Therapy
• Colonoscopy
• ADHD Testing
• Hernia Repair
• HIV Infection
• Chronic Fatigue Syndrome
• Osteoporosis
• New York City doctors
• Los Angeles doctors
• Chicago doctors
• By Location
• Newly Added Providers
• Telemedicine Doctors

• Institute of Haematology and Transfusion Medicine
• Posted on: 29 August 2024

PHD STUDENT IN MOLECULAR BIOLOGY, ONCOLOGY AND HEMATOLOGY

Job information, offer description.

Institute of Hematology and Transfusion Medicine in Warsaw, Poland, offers three  PhD candidate positions in the project “ Molecular mechanisms of DNA damage triggered by PIM kinases inhibition and its consequences for activation of innate immunity and anti-tumor response in diffuse large B-cell lymphoma” , supervised by prof. Przemysław Juszczyński, MD, PhD.

 Our group has recently demonstrated that blocking the activity of PIM kinases induces lymphoma cell death, but simultaneously increases the susceptibility of the tumor to the immune system attack (DOI:10.1158/0008-5472.CAN-21-1023). We have recently  started to characterize additional immunomodulatory mechanisms associated with PIM kinase inhibition. Since generated inflammatory signals may reshape tumor microenvironment from “cold” to “hot”, which helps the immune system to combat the tumor, we plan to characterize and understand in detail the mechanisms of PIM kinase inhibition-mediated immunomodulation. 

Institute of Hematology and Transfusion Medicine is one of the leading research institutions in Poland and a reference hematooncology center. Studies will be performed in a young, dynamic group, providing opportunities for successful publishing of research results. We offer scientific development oportunities, collaboration  with leading research institutions nationally and internationally and access to cutting-edge research technologies. 

Selected candidates will be enrolled to a do doctoral school. We offer two PhD fellowships ( 5000 PLN ) for the first two years, increased  after the interim evaluation (after 2 years). 

Where to apply

Requirements.

• Background biological (biology, biochemistry, molecular biology, biotechnology or related disciplines) or medical education
• Theoretical knowledge on the pathogenesis of lymphoid malignancies
• Hands-on experience in basic laboratory techniques used in in vitro cancer cell studies
• Laboratory experience in molecular biology, biochemical techniques and background in bioinformatics are welcome
• Fluency in English

Additional Information

REQUIRED DOCUMENTS

• CV, including, GPA, list of publications, research stays and other achievements 
• Copy of MSc/MD diploma
• Motivation letter
• At least one recommendation letter from former mentors/referees (sent directly to the Project leader   [email protected]
• Certificates of fluency in English, if available
• All documents must be submitted in English to [email protected]

PLEASE SUBMIT ALL THE REQUIRED DOCUMENTS IN ENGLISH, WITHIN A SINGLE PDF FILE.

The application documents should include the following statement:

„I hereby give consent to process my personal data included in my offer, for the purposes of the recruitment procedure, and to disclose my name and surname in the "recruitment results" section of the IHT website, by the Institute of Hematology and Transfusion Medicine, address: I. Gandhi 14 Str, Warsaw, Poland ; REGON 000849327, NIP 777-00-02-062 (further referred to as the Institute). I acknowledge that the Institute hereby becomes the administrator of my data. I have been acquainted with all the consequences resulting thereof, in particular with the following facts: 

1. For more details with regard to processing my personal data, I can contact the Data Protection Officer: [email protected]

2. My personal data are processed for the purposes of the recruitment procedure.

3. Members of the relevant recruitment committees are recipients of my personal data.

4. My personal data shall not be transferred to any Third Party.

5. My personal data will be processed for the period of 28 days upon the date when the recruitment procedure is concluded. Following this period, they will be irretrievably and effectively destroyed, so that they can no longer be accessed or reconstructed by any means.

At the same time, I acknowledge that I have the right to request from the Institute access to my personal data and the right to amend them or withdraw my consent to process them. I also declare that I have been informed about my right to file complaint to the President of the Office for Personal Data Protection, in the case when the Institute breaches the principles of processing my personal data, stipulated in the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC”.*

Work Location(s)

Share this page.